October 4, 2023

Phase 1 Study Supports Dose-Escalating Preoperative SRS for Large Brain Metastases

This approach led to local control for patients with brain metastases more than 2 cm in diameter

23-CNR-4210967-CQD-Hero-Astro

A research effort, led by Cleveland Clinic experts, demonstrated that preoperative stereotactic radiosurgery (SRS) with dose escalation followed by surgical resection for brain metastases larger than 2 cm led to local control that is similar to standard approaches (i.e., postoperative SRS or whole-brain radiation therapy), and with potentially fewer long-term side effects.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

These findings, “Results of a Phase 1 Trial of Dose Escalation for Preoperative Stereotactic Radiosurgery for Patients with Large Brain Metastases” were recently presented by Erin Murphy, MD, Associate Professor, Department of Radiation Oncology, Cleveland Clinic, during the ASTRO 2023 annual meeting.

“Single session stereotactic radiosurgery alone for certain brain metastases (>2 cm in diameter) typically leads to suboptimal local control,” says Dr. Murphy. “Additionally, surgical resection alone also results in unreliable local control and perioperative radiation is needed. We initiated this prospective, phase 1 trial to determine the safety of preoperative SRS at escalating doses followed by surgical resection.”

Methods and results

This study included three radiosurgery dose cohorts based on maximum tumor diameter of the index lesion: 18 Gy for >2-3 cm, 15 Gy for >3-4 cm and 12 Gy >4-6 cm. Concurrent stereotactic radiosurgery alone to other smaller lesions was permitted using standard RTOG dosing.

“Within each of these cohorts, we started at the base dose that we use for intact tumor dosing and escalated the dose at three gray (Gy) increments,” says Dr. Murphy. “If at least two patients enrolled safely at the base dose, we would escalate. If there was one dose limiting toxicity, we would continue to enroll until the time of escalation unless there was a second dose limiting toxicity. In those cases, the previous, lower dose was determined to be the maximum safe dose.”

The researchers defined dose limiting toxicity as grade 3 or greater acute toxicity within three to four months following SRS. Within two weeks of SRS, enrolled patients underwent surgical resection. They were then followed by the study authors with image and neurological evaluations every three months.

Advertisement

This analysis included 35 patients with a median age of 63 years. The median interval between SRS and surgery was two days. Among enrolled patients, the most common histology was non-small cell lung cancer (57.1%), followed by breast cancer (14.3%).

Patients with a tumor size of >2-3 cm were enrolled up to the second dose level (21 Gy). The third dose level was reached for patients in the >3-4 cm and >4-6 cm cohorts (21 Gy and 18 Gy, respectively).

Study authors observed a total of three dose limiting toxicities. Two occurred in the >3-4 cm cohort (grade 3 wound dehiscence and grade 3 wound infection) and one in the >4-6 cm group (grade 4 hematoma).

“We determined that the maximum tolerable dose was 18 Gy (2nd dose level) for the >3-4 cm cohort, and 18 Gy (3rd dose level) for the >4-6 cm group,” says Dr. Murphy, while discussing their key findings.

“At two years, the rate of leptomeningeal disease was 0%,” she reports. “This suggests a significant benefit over post-operative radiosurgery, which demonstrates a higher rate of leptomeningeal disease. Additionally, we observed good local control after long-term follow up. At a median median follow-up of 64 months, the six- and 12-month local control rates were 88.8% and 79.1%, respectively.”

Advertisement

Dr. Murphy and her colleagues also found that preoperative stereotactic radiosurgery with dose escalation followed by surgical resection led to six- and 12-month distant brain control of 63.1% and 55.3%, respectively. Overall survival at six and 12 months was 82.9% and 59.0%.

Conclusions and next steps

Based on these phase 1 findings, further investigation of this approach is warranted, according to Dr. Murphy. The research team has opened the phase 2 arm of this trial, and enrollment is ongoing. The study will be conducted at the maximum tolerated doses, and patients will be followed for efficacy and toxicity outcomes.

“Preoperative SRS with dose escalation followed by surgical resection has the potential to benefit a variety of patients with brain metastases,” says Dr. Murphy. “In this era of more molecular-targeted therapies and immunotherapies, patients who have brain metastases are living longer. Finding approaches that give patients, especially those who present with large tumors, durable control is important.”

Related Articles

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

23-CNR-4318382-CQD-Hero-650×450 Dr Hill
December 19, 2023
Active Surveillance may be a Feasible Option for a Subset of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients

Dr. Caimi
December 15, 2023
CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

Ad